A hospital pharmacist in Belgium has a treatment schedule confirmed for the coming weeks, and the usual wholesaler cannot confirm stock of an injectable oncology product. A procurement manager elsewhere in the EU is told a substitute pack from another market is available, but nobody can say whether the labelling, documentation or storage history will be acceptable. In both cases, the question is the same: how do you judge an oncology medicine supplier Europe-wide when the product cannot wait and the paperwork must still be right?
Key points
- Oncology products combine tight timelines, temperature sensitivity and strict documentation, so supplier checks need to be more detailed than for routine lines.
- Verify the legal status of the product in the destination country before you discuss price or delivery.
- Ask for evidence of GDP compliance, temperature records and batch-level documents, not general assurances.
- Agree in advance how shortages, recalls and urgent requests will be handled.
Why oncology sourcing needs a different approach
Many oncology medicines are given on a fixed schedule, prepared in hospital pharmacy under controlled conditions, and supplied in presentations that are sensitive to heat, light or handling. A delay or a documentation gap therefore affects the clinical team directly. Buyers rarely have the luxury of waiting for a second quotation.
Supply is also uneven across member states. A product may be authorised and marketed in one country, withdrawn commercially in another, and available only through a different pack presentation in a third. Pricing and reimbursement arrangements differ, which means a purchase that is straightforward in one market may need extra steps in yours.
This is why a buyer-side checklist helps. It turns a stressful request into a series of questions that can be answered, recorded and audited later.
What to check before you choose an oncology medicine supplier Europe-wide
1. Legal status of the product in your country
Start with the basics. Is the exact product authorised in your member state, either nationally or through the centralised procedure under Regulation (EC) No 726/2004? If it is, check that the supplier is offering that authorised presentation and not a pack intended for another market.
If the product is not authorised locally, the route changes. Your national competent authority may allow supply under a special-needs or named-patient mechanism, usually with a prescriber request and specific records. Our earlier article on sourcing unlicensed medicines in Europe explains how that process works in practice.
2. Licences held by the supplier and its sites
A supplier handling medicines in the EU should hold the relevant wholesale distribution authorisation, and, where it imports from outside the EEA, the appropriate importation authorisation or work with a holder who does. Ask for copies and check them against the national or EudraGMDP databases rather than relying on a certificate sent by email.
Look at the whole chain, not only the contracting company. Where are the goods stored, who transports them, and who releases batches? Gaps usually appear in the handovers between parties.
3. GDP compliance and warehouse evidence
Good Distribution Practice sits at the centre of any supplier qualification. Ask which warehouses will hold your product, when they were last inspected, and how deviations are recorded and closed out. A supplier that can describe its own deviation process in plain terms is usually one that follows it.
Ikris Pharma Network, for example, operates EU-GDP-certified warehouses in Belgium and Bulgaria, and handles oncology alongside rare diseases, haematology, nephrology, cardiology and critical care. Whichever supplier you assess, the principle is the same: ask for the certificate, the site name and the scope, and match them to the product category you need.
4. Temperature control and transport records
Many oncology medicines require refrigerated storage and transport. Ask what temperature range applies to your product, how it will be monitored during shipment, and what happens if an excursion is recorded. You should expect a clear answer on who decides whether a product with a recorded excursion can still be used, and on what evidence.
Request the data logger output for each consignment, not only a statement that the shipment was within range. Agree in advance who holds responsibility at each stage, including customs clearance and weekend delivery.
5. Batch documents and traceability
Each delivery should come with the documents your quality team needs to release the batch. Typically this includes the batch certificate, a certificate of analysis where applicable, delivery notes that identify the supply chain, and evidence of the batch release by the responsible party in the EU or EEA.
Traceability matters in both directions. If a recall or quality alert occurs, you need to identify affected batches quickly, and the supplier needs to tell you which customers received them. Ask how this works and how quickly the supplier can respond.
6. Safety features, labelling and language
Prescription medicines for the EU market generally carry safety features under Directive 2011/62/EU and Commission Delegated Regulation (EU) 2016/161, which includes a unique identifier and an anti-tampering device. A pack from another market, or one imported under a special route, may not meet those requirements in the same way.
Check what the labelling and patient information will look like in your country. Hospital pharmacy teams should know before the delivery arrives whether relabelling, over-labelling or an accompanying translation is needed, and who will carry it out under the proper authorisation.
Questions on continuity and communication
Once the formal checks are complete, the practical ones matter just as much. A supplier may be fully compliant and still be a poor fit if it cannot respond when stock moves.
- How do you tell us about supply constraints at manufacturer level, and how early?
- Can you offer an alternative authorised presentation or source if the original is unavailable?
- Who is our named contact for urgent requests, and what are the working arrangements outside normal office hours?
- What is your process for a quality complaint, and who in your organisation signs off the investigation?
- How do you handle shipments to another member state, including import or export paperwork when the product is moved across borders?
Cross-border movements add their own questions about licences and responsibilities. Our article on cross-border drug sourcing in the EU covers those points in more detail.
Common mistakes hospital buyers make
The first is treating price as the opening question. A low quotation for a product that cannot be legally supplied, or that arrives without complete records, is not a saving. It is a delay waiting to happen.
The second is accepting a verbal description of the product. Presentation, strength, pack size and manufacturer can differ between markets even when the active substance is the same. Ask for the exact product details in writing and have your pharmacy team confirm them.
The third is leaving quality agreements until after the first order. If the responsibilities for storage, transport, complaints and recalls are not written down, they will be decided under pressure the first time something goes wrong.
The fourth is relying on a single source. Where your policy permits, qualify an additional supplier before you need one. Qualification takes time, and urgent requests are the wrong moment to start it.
Where a procurement partner fits
Some hospitals and distributors have the in-house capacity to qualify and manage many suppliers. Others prefer to work with a partner that already holds the supplier relationships, storage capability and documentation processes, and can apply them to a specific request. Our pharmaceutical procurement service is set up for that kind of requirement, and the team works with hospitals, distributors, importers, NGOs and procurement teams.
Whichever route you choose, keep your own quality function involved. A partner can reduce the workload, but the responsibility for the medicines you administer stays with your institution.
A short pre-order checklist
- Confirm the legal route for the exact product in your country.
- Check the supplier’s licences and the sites involved against official databases.
- Review GDP evidence, including warehouse scope and recent inspection outcomes.
- Agree the temperature requirements, monitoring and excursion procedure.
- List the batch documents your quality team requires and confirm they will be supplied.
- Confirm labelling, safety features and language arrangements.
- Document the recall, complaint and shortage communication process.
Frequently Asked Questions
Can any EU wholesaler supply oncology medicines?
Only if it holds the right authorisation and can handle the product under the storage and transport conditions it requires. Check that the licence scope and the warehouse match the product category.
What if the product I need is not authorised in my country?
Some member states permit supply of an unauthorised product for an individual patient or defined need, subject to national rules and prescriber involvement. Speak to your competent authority and your supplier early, as the requirements differ between countries.
Should I accept a pack intended for another EU market?
Not without checking. Labelling, language, safety features and the authorised presentation may differ, and your regulator may have specific expectations for how such packs are handled.
How should I assess cold chain performance?
Ask for the monitoring data from each shipment and the supplier’s written procedure for temperature excursions. A statement that the shipment arrived in good condition is not sufficient evidence.
If you are reviewing options for an oncology requirement and would like to discuss documentation, routes or timelines, please contact the Ikris Pharma Network team through our contact page.
